HER2+ Metastatic Breast Cancer in Kazakhstan (observational)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study plans to enroll about 240 adults with HER2-positive metastatic breast cancer treated with anti-HER2 therapy across 12 centers in different regions of Kazakhstan. Participants will be enrolled in order of diagnosis date within a defined timeframe, and retrospective follow-up will extend at least 12 months after the latest diagnosis to capture outcomes. Data collection focuses on real-world treatment patterns and outcomes without a specified intervention. Key eligibility requires documented HER2-positive metastatic disease diagnosed between 2022 and 2023 and at least 24 months of follow-up data unless death, relocation, or early discontinuation occurs. The study is sponsored by AstraZeneca and involves sites in Oral, Aktobe, and Almaty.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion
* The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023
* Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis
* Age ≥18 years at the time of inclusion

Exclusion Criteria:

* Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection
* Patients received trastuzumab deruxtecan
* The participation in any interventional trial within period since diagnosis until the end of study

Where it's running

• Research Site
  Oral, Kazakhstan, Kazakhstan Recruiting
• Research Site
  Almaty, Kazakhstan Recruiting
• Research Site
  Almaty, Kazakhstan Recruiting
• Research Site
  Astana, Kazakhstan Recruiting
• Research Site
  Astana, Kazakhstan Recruiting
• Research Site
  Karaganda, Kazakhstan Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Personalized treatment after endocrine therapy failure in metastatic breast cancer

  The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07895160

• SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer

  This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.

  Recruiting Phase 2 Shenyang Sunshine Pharmaceutical Co., LTD. · Guangzhou, Guangdong · NCT07757230

• SMP-656 in HER2-positive advanced breast cancer after ADC therapy

  This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.

  Recruiting Phase 2 Chengdu SciMount Pharmatech Co., Ltd. · Hefei, Anhui and 14 other locations · NCT07726342

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.